PROJECT

Projects

Environmental & Social Review Summary

Project Number

38371

Company Name

GLENMARK PHARMACEUTICALS LIMITED

Date ESRS Disclosed

Jun 15, 2016

Country

India

Region

South Asia

Last Updated Date

Jun 25, 2022

Environmental Category

B - Limited

Status

Completed

Previous Events

Approved : Jun 22, 2016
Signed : Jun 24, 2016
Invested : Jun 28, 2016

Sector

Pharmaceuticals and Medicine

Industry

Health, Education and Life Sciences

Department

Regional Industry - MAS Asia & Pac

Project Description

Founded in 1977, Glenmark Pharmaceuticals Limited (“Glenmark” or “the company”) is a leading Indian manufacturer of generic pharmaceuticals. The company engages in the development, manufacturing, and marketing of pharmaceutical products and active pharmaceutical ingredients (APIs) in India and internationally, and offers products in a range of therapies including respiratory, dermatology, cardiovascular and oncology.

The company has a global presence in more than 60 countries and 17 manufacturing facilities across India, United States (US), Argentina and Czech Republic. Of the 13 manufacturing facilities in India, five are API manufacturing facilities and located at Mohol, Kurkumbh and Aurangabad (in Mahrashtra), and Ankleshwar and Dahej (in Gujarat); the remaining are formulation facilities in Baddi and Nalagarh (in Himachal Pradesh), Nashik and Aurangabad (in Maharashtra), Indore (Madhya Pradesh), Sikkim and Goa. In addition, all overseas facilities are formulation facilities.

The company is also involved in the discovery of new chemical entities and new biological entities and has five Research and Development (R&D) centers across India and Switzerland.

The proposed investment is upto $75 million through quasi-equity instruments to be used for; (a) expanding manufacturing capacity (primarily in India); (b) building R&D capacity for new products (including in India); and (c) reduce debt so that internal accruals can be deployed to R&D (“the project”).

Overview of IFC's Scope of Review

Considering the nature of the proposed investment (i.e. a corporate investment) and footprint of the company, the focus of IFC’s review was to understand the capacity, maturity and reliability of the Glenmark’s corporate environmental and social (E&S) management systems so as to effectively manage its E&S performance; the latter also included assessment of the company’s ability to ensure current and ongoing compliance with IFC’s Performance Standards (PSs). To understand typical E&S risks and impacts associated with the pharmaceutical manufacturing operations which need/will need to be managed, the E&S performance of a sample of Glenmark’s existing pharmaceutical operations in India were reviewed during the appraisal.


In 2013, IFC had evaluated operations of one of Glenmark’s facilities in Goa for a proposed financial partnership, however, the project was not completed. The information available from that appraisal also provided a background to IFC on E&S management at Glenmark.

Taking the above into account, IFC’s appraisal consisted of reviewing company information related to technical, environmental, health and safety (EHS) and social matters including: corporate EHS policies and procedures, EHS performance reports submitted by facilities, management systems information (internal audits, objectives and targets, procedures), regulatory permits, EHS organization charts, environmental and workplace monitoring reports, safety audits, on-site emergency response plans, EHS training records and human resource (HR) related records. The appraisal also included site visits (in May 2016) to the operational API manufacturing facilities at Ankleshwar and Mohol, and a formulation facility at Baddi. Further, discussions were held with management at the respective facilities (representatives from EHS, HR, engineering and production), as well as the corporate office including Head - EHS, and individuals from HR and the supply chain management teams.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan